News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
TUCSON, Ariz. , Sept. 26, 2022 (GLOBE NEWSWIRE) --  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald
View HTML
Toggle Summary The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test
TUCSON, Ariz. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2022 Results
Call scheduled for today, August 11, 2022, at 4:30 pm ET TUCSON, Ariz. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11
TUCSON, Ariz. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended
View HTML
Toggle Summary HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz. , July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will host a key opinion leader (KOL) webinar on “ Drug
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Amendment to Senior Loan Facility
TUCSON, Ariz. , July 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced it has entered into an amendment of its June 24, 2020 Loan and
View HTML
Toggle Summary HTG Releases Second Whitepaper for its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz. , July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released a second white paper (the “White Paper”), further establishing the
View HTML
Toggle Summary Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer
TUCSON, Ariz. , June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced the customer publication of a peer reviewed journal article featuring
View HTML
Toggle Summary HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials
TUCSON, Ariz. , June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be sponsoring a keynote presentation at the 7 th Annual
View HTML
Toggle Summary HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASCO 2022
TUCSON, Ariz. , June 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced its HTG EdgeSeq technology was highlighted in multiple
View HTML